Imfinzi plus chemotherapy tripled patient survival at 3 years
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Subscribe To Our Newsletter & Stay Updated